Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RNA NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$12.72-1.8%$13.43$11.95▼$16.77$217.59M0.93605,753 shs168,126 shsSRPTSarepta Therapeutics$17.12+2.9%$20.02$10.41▼$44.14$1.76B0.263.14 million shs2.29 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences-1.78%-4.36%-11.05%-82.54%-59.80%SRPTSarepta Therapeutics+2.88%-9.13%-20.07%-7.91%-57.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$12.72-1.8%$13.43$11.95▼$16.77$217.59M0.93605,753 shs168,126 shsSRPTSarepta Therapeutics$17.12+2.9%$20.02$10.41▼$44.14$1.76B0.263.14 million shs2.29 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences-1.78%-4.36%-11.05%-82.54%-59.80%SRPTSarepta Therapeutics+2.88%-9.13%-20.07%-7.91%-57.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRNAAvidity Biosciences 2.37Hold$69.42445.76% UpsideSRPTSarepta Therapeutics 2.11Hold$27.7161.85% UpsideCurrent Analyst Ratings BreakdownLatest RNA and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026RNAAvidity Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/1/2026RNAAvidity Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral4/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell4/7/2026SRPTSarepta Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$18.00 ➝ $19.003/26/2026SRPTSarepta Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $35.003/26/2026SRPTSarepta Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.00 ➝ $14.003/26/2026SRPTSarepta Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$9.00 ➝ $13.003/26/2026SRPTSarepta Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform3/19/2026SRPTSarepta Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRNAAvidity Biosciences$36.68M5.93N/AN/A$10.88 per share1.17SRPTSarepta Therapeutics$2.20B0.82N/AN/A$14.26 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRNAAvidity Biosciences-$322.30MN/AN/AN/AN/A-3,650.39%-44.92%-39.57%N/ASRPTSarepta Therapeutics-$713.41M-$0.96N/A7.480.19-2.94%7.56%2.94%8/5/2026 (Estimated)Latest RNA and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 million2/23/2026Q4 2025RNAAvidity Biosciences-$1.24-$1.59-$0.35-$1.59$1.98 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthRNAAvidity BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRNAAvidity BiosciencesN/A9.2011.57SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRNAAvidity BiosciencesN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipRNAAvidity Biosciences3.83%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRNAAvidity Biosciences19017.11 million149.21 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableRNA and SRPT HeadlinesRecent News About These CompaniesWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20 at 1:15 PM | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20 at 9:31 AM | insidermonkey.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19 at 12:43 PM | proactiveinvestors.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 17, 2026 | theglobeandmail.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.comSarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target UnchangedMay 15, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)May 14, 2026 | theglobeandmail.comSarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft FoundationsMay 14, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | businesswire.comSarepta Therapeutics (SRPT) Gets a Buy from OppenheimerMay 12, 2026 | theglobeandmail.comWells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)May 11, 2026 | theglobeandmail.comA Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline ProgressMay 9, 2026 | finance.yahoo.comVanguard Group Inc. Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPTMay 9, 2026 | marketbeat.comSarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush SaysMay 8, 2026 | finance.yahoo.comSarepta (SRPT) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comSRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growthMay 8, 2026 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% - Should You Sell?May 7, 2026 | marketbeat.comSarepta Therapeutics, Inc. Q1 2026 Earnings Call SummaryMay 7, 2026 | app.moby.coASarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.May 7, 2026 | finance.yahoo.comSarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?May 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNA and SRPT Company DescriptionsAvidity Biosciences NASDAQ:RNA$12.72 -0.23 (-1.78%) As of 05/20/2026 04:00 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Sarepta Therapeutics NASDAQ:SRPT$17.12 +0.48 (+2.88%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$17.14 +0.02 (+0.15%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
